Global Pediatric Drugs Market to Reach $227.67 Billion by 2031 as Illness-Driven Demand Grows
Updated
Updated · Yahoo Finance · Aug 20
Global Pediatric Drugs Market to Reach $227.67 Billion by 2031 as Illness-Driven Demand Grows
1 articles · Updated · Yahoo Finance · Aug 20
Summary
$227.67 billion is the projected size of the global pediatric drugs market in 2031, up from $141.27 billion in 2025 and $152.97 billion in 2026.
An 8.29% CAGR through 2031 is tied to rising childhood obesity, respiratory disease, neurological disorders, cancer and rare genetic conditions, alongside demand for safer age-appropriate formulations.
Drugmakers are increasingly building pediatric-specific therapies rather than adapting adult medicines, with examples ranging from liraglutide for children aged 6 to 12 to newer rare-disease treatments such as KEBILIDI.
Regulatory support is reinforcing that pipeline: the FDA had issued 38 rare pediatric disease priority review vouchers through 2024 and logged 569 designations since 2013, while Asia-Pacific is seen as a major growth opportunity.